Does Depression Cause Low Libido, or Is It the Antidepressant?
Share
Does depression cause low libido? Often, yes, and usually before any prescription exists. Pooled across 12 studies of people diagnosed with major depressive disorder who were taking no drug treatment at all, 65.3% of the women and 40.3% of the men reported impaired sexual desire. In a separate community survey of 2,020 midlife women, moderate to severe depressive symptoms carried an odds ratio of 2.69 for low-desire dysfunction, while psychotropic medication use in that same statistical model carried 1.42. In that one model, the illness carried more weight than the medication did.
- Untreated depression already suppresses desire. In a meta-analysis restricted to people with depressive disorders taking no medication, desire impairment ran to 65.3% in women and 40.3% in men.
- In the Worsley survey of 2,020 Australian women aged 40 to 65, moderate to severe depressive symptoms sat second on the predictor list at OR 2.69. Being partnered sat first at 3.30. Anyone who tells you depression topped that list has misread the paper.
- The best RCT evidence on SSRIs points at orgasm, RR 3.28 and high certainty on the authors' own GRADE assessment. For desire, the same meta-analysis found a trend that did not reach significance.
- The arrow runs both ways. In pooled prospective cohorts, sexual dysfunction predicted later depression at an adjusted OR of 3.12, a stronger signal than the reverse at 1.71.
- Antidepressant sexual side effects are real and common: 59.1% of 1,022 outpatients, when a questionnaire asked directly. That is a reason to talk to your prescriber, and never a reason to stop a medication on your own.
- NUUD is a botanical supplement for desire. It does nothing for depression, it replaces no part of your care, and this article is education.
Figures from Goncalves et al. 2023 (PMID 35194149), Worsley et al. 2017 (PMID 28499520), and Montejo et al. 2001 (PMID 11229449). The two odds ratios come from one cross-sectional model and describe association.
What depression does to desire before anyone writes a prescription
The cleanest way to separate the illness from the drug is to look at people who have the illness and have never taken the drug. Goncalves and colleagues pooled 12 cross-sectional studies of sexual function in major depressive disorder and persistent depressive disorder, restricted to people who were not in pharmacological treatment.
In women with major depressive disorder, 65.3% (95% CI 45.9 to 84.7) had impaired sexual desire. In men, 40.3% (95% CI 22.2 to 58.5). Overall sexual dysfunction of any kind reached 82.8% of the women and 63.3% of the men (Goncalves et al., 2023). Nobody in those samples was on an antidepressant. There was no prescription to blame.
Look at that first confidence interval before you carry the number anywhere. A spread from 45.9% to 84.7% is what 12 cross-sectional studies with different instruments produce. The honest reading is that desire impairment in untreated depression is common and the exact rate is unsettled.
The severity gradient shows up too. At a Brazilian outpatient clinic for treatment-resistant depression, 65 consecutive patients were assessed at intake using a single item from the Hamilton Depression Rating Scale as a proxy for sexual desire. Desire was impaired in 67.7% of them, and greater depression severity tracked with worse scores at P less than .01 (Goncalves et al., 2022). Treat that one carefully. Sixty-five people at a specialist clinic for depression that has already failed multiple treatments is close to the hardest population in psychiatry, and a single scale item is a blunt proxy. It shows you the ceiling, and the average person on a first antidepressant sits somewhere well below it.
The predictor list, ranked honestly
The most-quoted paper here is Worsley 2017, a cross-sectional, nationally representative survey of 2,020 Australian women aged 40 to 65. It used the desire domain of the Female Sexual Function Index, the Female Sexual Distress Scale-Revised, and the Beck Depression Inventory-II with a cutoff of 20 or higher for moderate to severe depressive symptoms.
Low desire came in at 69.3% of the sample, sexually related personal distress at 40.5%, and the combination of the two, which the paper calls hypoactive sexual desire dysfunction, at 32.2%.
Then the adjusted logistic regression, which is where people go wrong. Six factors were associated with that combined outcome.
Every predictor in the Worsley adjusted model, ranked
Odds ratios for hypoactive sexual desire dysfunction in 2,020 Australian women aged 40 to 65. Horizontal bars are 95% confidence intervals. Orange marks the two this article compares.
Source: Worsley R, Bell RJ, Gartoulla P, Davis SR. J Sex Med 2017 (PMID 28499520). All six values and intervals are printed in the RESULTS section of the abstract. Cross-sectional design, so these are associations. The paper did not measure testosterone or estradiol and did not examine hormone therapy.
Depression came second. Being partnered came first, at OR 3.30, a bigger number than anything else in the model. That ordering matters, because the outcome here is low desire plus distress about it, and a woman with a partner has a standing reason to be distressed about low desire that an unpartnered woman may not have. The paper does not offer that explanation, so treat it as our reading of the partnership variable. The paper does report that 32.4% of women who were unpartnered or sexually inactive still reported sexually related distress.
Moderate to severe depressive symptoms, 2.69. Psychotropic medication use, 1.42. Same cohort, same adjusted model, same outcome. The illness carried roughly 1.9 times the odds the medication did, and the confidence intervals do not overlap, since 1.99 sits above 1.83. Two things keep that from being a slam dunk. Worsley never tested whether those two odds ratios differ from each other, and non-overlapping intervals are only suggestive on their own. And "psychotropic medication" is a broad bucket covering antidepressants, sleep drugs, and anxiety drugs together, so it makes a rough SSRI proxy at best.
Which arrow points which way
Cross-sectional surveys catch everything at one moment, so they cannot tell you what came first. For that you need people followed forward in time.
Atlantis and Sullivan pooled prospective cohorts in both directions: six studies covering 3,285 participants followed 2 to 9 years for depression predicting later sexual dysfunction, and six covering 11,171 participants followed 1 to 10 years for the reverse. Depression raised the risk of later sexual dysfunction at a pooled unadjusted RR/OR of 1.52 (1.02 to 2.26) and an adjusted 1.71 (1.05 to 2.78). The partially adjusted model came out at 1.41 (0.90 to 2.23), which crosses 1.0 and misses statistical significance (Atlantis and Sullivan, 2012).
The reverse arrow was stronger. Sexual dysfunction raised the odds of later depression at an unadjusted OR of 2.30 (1.74 to 3.03), an adjusted 3.12 (1.66 to 5.85), and a partially adjusted 2.71 (1.93 to 3.79). Every one of those clears 1.0 comfortably. The authors reported significant heterogeneity between studies in both examinations, and their meta-regression found no source for it.
The loop is real and runs both ways. The stronger measured signal goes from a dead sex life into depression. If you have spent a year assuming your flat desire is a symptom of your mood, the prospective data says it may equally be feeding it. A person carrying a year of quiet failure in bed is carrying a genuine risk factor, and that is worth saying out loud to whoever is treating you.
The medication half, in one section
Antidepressant sexual side effects are real and common, and this site has already covered them in depth.
Montejo and colleagues ran a prospective, open-label, multicenter study through the Spanish Working Group, collecting data from April 1995 to February 2000 on 1,022 outpatients (610 women, 412 men, mean age 39.8) who had normal sexual function before starting an antidepressant, each interviewed with the Psychotropic-Related Sexual Dysfunction Questionnaire. Overall incidence of any sexual dysfunction was 59.1%, or 604 of 1,022 people. By drug: fluoxetine 57.7%, sertraline 62.9%, fluvoxamine 62.3%, paroxetine 70.7%, citalopram 72.7%, venlafaxine 67.3%. Drugs with other mechanisms landed far lower: mirtazapine 24.4%, nefazodone 8%, amineptine 6.9%, moclobemide 3.9% (Montejo et al., 2001). The design limits what those numbers can settle. It was open-label and unblinded with no placebo arm, so it measures how often the problem turns up, and it cannot separate the drug from the depression underneath. That is the job the placebo-controlled trials below do. The authors also open the paper by saying the incidence is underestimated and that a specific questionnaire is needed to find it. Nobody volunteers this in a ten-minute appointment.
The randomized evidence complicates that. Dagostin Ferraz and colleagues screened trials up to June 2025, included 13 RCTs, and meta-analyzed six against placebo. SSRIs raised the risk of orgasmic dysfunction at RR 3.28 (2.33 to 4.60, I squared 8%) and reduced sexual satisfaction at RR 1.21 (1.11 to 1.32). Sexual desire showed a trend that did not reach significance: RR 1.40 (0.92 to 2.12, P = .12, I squared 54%). Total CSFQ scores showed no difference against placebo. Their GRADE assessment, quoted from the paper's CONCLUSION, rates orgasmic dysfunction as high certainty and sexual desire disorders as moderate certainty (Dagostin Ferraz et al., 2026).
Together those two paragraphs split cleanly. The placebo-controlled evidence for SSRIs hitting orgasm is strong. The placebo-controlled evidence for SSRIs hitting desire probably exists and did not clear significance in this pooled analysis, and "probably" is doing exactly the work that moderate-certainty GRADE rating licenses it to do.
Everything else about the drug half lives in the four articles built for it: what doctors do not say about antidepressants and libido, what actually helps when an SSRI flattens your drive, SSRIs stacked on top of perimenopause, and what happens to libido after you stop. Whichever of those applies to you, do not stop, reduce, or change an antidepressant on your own. That is a conversation with the person who prescribed it.
Depression and the antidepressant, side by side
| Question | The depression itself | The antidepressant |
|---|---|---|
| Strongest evidence | 12-study pooled prevalence in people with depressive disorders taking no medication (PMID 35194149) | 13 RCTs screened, 6 meta-analyzed against placebo (PMID 41721013) |
| Which part of sex it hits hardest | Desire. 65.3% of unmedicated women, 40.3% of unmedicated men | Orgasm. RR 3.28 against placebo, high certainty. The desire signal was RR 1.40 and did not reach significance |
| Odds in one midlife-women model | Moderate to severe depressive symptoms, OR 2.69 (1.99 to 3.64) | Psychotropic medication use, OR 1.42 (1.10 to 1.83). Broad drug bucket, so it is a rough proxy |
| Timing you would expect | Tracks the episode. Present before treatment ever started, and worse as severity rises | Starts after the drug does, often within the first weeks or after a dose increase |
| What addressing it involves | Treating the depression properly with your clinician, and giving remission time to hold | A prescriber conversation about dose, timing, or a switch. Never a solo decision |
| What it fails to explain | Desire that vanished in the two weeks after a dose change, while mood was steady | Desire that was already gone before the first tablet, or still gone months after the last one |
"I stopped the meds and it's still gone"
That sentence sends people looking for a third explanation. If desire was already flat before the prescription, the drug was never the whole story. If it is still flat after the drug is out of your system, the drug is not the current story either.
Which lane are you in?
Lane descriptions are our reading of the evidence cited on this page, offered as a way to organize a conversation with your clinician. They are not a diagnostic tool.
"Brain fog, no energy, no drive"
People rarely walk in describing low desire. They describe the package: nothing is interesting, everything is heavy, the phone is exhausting, and sex fell off the list somewhere along the way without a specific date.
Anhedonia is the clinical name for the loss of pleasure and interest, and it is one of the two core symptoms required to diagnose major depression. Sexual interest is one of the appetites it flattens, alongside food, music, work, and company. Framed that way, a dead libido during a depressive episode is that same symptom arriving at one more address.
That reframe stops the search for a hormone or a supplement that will fix one appetite while the other five stay flat. It also explains why the numbers can come back fine while you feel exactly the same, a pattern we wrote up in what to do when your labs are normal and your libido has not moved.
Shame is the part nobody prints. A person whose desire has been gone for two years usually believes something is broken in them specifically, and that belief does its own damage on top of the depression. The mechanism behind it is well documented and it is common, which is worth knowing before you turn it into a verdict on yourself. If the shame has become its own layer, low libido, trauma, and shame goes deeper than we can here.
What treating the depression first actually looks like
"Treat the depression first" is easy to say and it lands badly if it sounds like an instruction to abandon everything else and wait. The practical version runs like this.
- Date the timeline before you theorize about it. Write down when desire changed, when the depression started, and when each medication started or changed. Most people discover the order differs from the story they have been telling, and that order is the most useful thing you can hand a clinician.
- Say the sexual part out loud at the appointment. Montejo's group found 59.1% incidence only because they asked 1,022 people with a structured questionnaire, and they open the paper by saying the incidence is otherwise underestimated. Your clinician is unlikely to raise it. You have to.
- Aim at remission, and give it a real window. Partial improvement leaves the symptom that flattens appetites still running. Depression severity tracked with worse desire scores in the treatment-resistant cohort at P less than .01, so severity is the lever with the most evidence behind it.
- Re-measure after the mood lifts, before you draw conclusions. Desire that returns as the episode lifts puts you in Lane 1. Desire that stays flat through a genuine remission tells you to widen the search. You cannot get either answer while you are still in the episode.
- Work the free levers in parallel. Sleep, alcohol, movement, and the state of the relationship all sit in the same picture. Alcohol carried its own OR of 1.48 in the Worsley model, covered in does alcohol lower libido. None of these cost anything.
One plain thing, said once. If you are having thoughts of hurting yourself, call or text 988 in the US and talk to someone today. That is more urgent than anything else on this page.
"I just want to feel normal again"
That sentence turns up more than any other in this category, and it is a reasonable thing to want.
NUUD is a botanical supplement built for desire. It does nothing for depression. It treats no condition, it replaces no part of your care, and it is no reason to change anything a prescriber has you on. If a depressive episode is what flattened your desire, the episode is what needs attention, and a capsule is not a substitute for that work.
It can sit alongside. Once the mood side is genuinely being handled and the free levers are in place, some people want one more thing to try on the desire side specifically. The formula is built on the NUUD Mushroom Complex™ at 150mg, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a 30 to 60 minute timeline. If that is honestly where you are in the sequence, our women's libido gummies are built for that spot and nothing beyond it.
Sleep, alcohol, and an honest conversation with your partner are free, and on the evidence in this article they belong ahead of anything you can buy.
Keep reading
- Antidepressants and low libido: what doctors do not say
- SSRI libido drop: what actually helps
- SSRIs, perimenopause, and low libido
- Libido after stopping antidepressants
- Normal labs, low libido
- Brain fog and sex drive
- Low libido, trauma, and shame
- Does alcohol lower libido
Frequently asked questions
Does depression cause low libido?
Often, yes, and the effect shows up before any medication does. A meta-analysis of 12 studies in people with depressive disorders who were taking no drug treatment found impaired sexual desire in 65.3% of the women and 40.3% of the men, though the confidence interval on the women's figure is wide at 45.9% to 84.7%. In a separate cross-sectional survey of 2,020 midlife women, moderate to severe depressive symptoms were associated with low-desire dysfunction at an odds ratio of 2.69, second on a six-factor list behind being partnered at 3.30. These are associations from observational data, so they show a strong and consistent link and cannot prove direction on their own.
Is it the depression or the antidepressant?
The timeline usually answers it. If desire was already flat before your first prescription, the illness is the better explanation, and the untreated-depression prevalence data supports that. If desire dropped in the weeks after starting a drug or raising a dose while your mood was steady, the medication is the better explanation. In the Worsley model both were present and the illness carried the larger odds ratio, 2.69 against 1.42 for psychotropic medication use, although that medication category is a broad bucket and the paper never tested the two numbers against each other. Take your dated timeline to your prescriber, and do not change a dose on your own.
I stopped the meds and it's still gone. What does that mean?
Most often it means the drug was never carrying the whole thing. Two candidates fit that pattern. The depression may still be active underneath, which the prevalence data in unmedicated patients would predict. Or something else moved in while you were unwell, such as short sleep, alcohol, pain, or a relationship that went quiet for a year. It is also worth checking whether the depression was ever treated to full remission, since depression severity tracked with worse desire scores in a treatment-resistant cohort at P less than .01.
Does treating the depression bring desire back?
Sometimes, and the honest answer is that this specific question is under-studied. The evidence establishes that untreated depression is associated with impaired desire, and that severity tracks with how bad it gets. What almost nobody has run is a clean trial following desire through remission and out the other side. Two findings are worth holding while you wait. Antidepressants themselves carry sexual side effects that can mask a recovery, at 59.1% incidence in one 1,022-patient study. And in pooled prospective cohorts the arrow ran in both directions, with sexual dysfunction predicting later depression at an adjusted odds ratio of 3.12.
Can a libido supplement help if I am depressed?
No supplement treats depression, and NUUD makes no claim to. A botanical supplement works on the desire side only, and if a depressive episode is what flattened your desire, then the episode is what needs treating. Anything you buy sits alongside that care and never in place of it. If you want a sequence: treat the depression with your clinician, deal with sleep and alcohol, keep talking to your partner, and consider a supplement after those are genuinely handled. Do not stop, reduce, or change an antidepressant on your own.
References
- Worsley R, Bell RJ, Gartoulla P, Davis SR. Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women. The Journal of Sexual Medicine. 2017. https://pubmed.ncbi.nlm.nih.gov/28499520/
- Goncalves WS, Gherman BR, Abdo CHN, Coutinho ESF, Nardi AE, Appolinario JC. Prevalence of sexual dysfunction in depressive and persistent depressive disorders: a systematic review and meta-analysis. International Journal of Impotence Research. 2023. https://pubmed.ncbi.nlm.nih.gov/35194149/
- Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. The Journal of Sexual Medicine. 2012. https://pubmed.ncbi.nlm.nih.gov/22462756/
- Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry. 2001. https://pubmed.ncbi.nlm.nih.gov/11229449/
- Dagostin Ferraz S, Kuyunga L, Rech P, et al. Sexual dysfunction associated with selective serotonin reuptake inhibitors in adults with depression: a systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2026. https://pubmed.ncbi.nlm.nih.gov/41721013/
- Goncalves WDS, Lassen RDH, Sardinha A, Coutinho ESF, Baldwin DS, Nardi AE, Appolinario JC. Impairment of Sexual Desire in Treatment-Resistant Depression: Prevalence and Correlates. The Primary Care Companion for CNS Disorders. 2022. https://pubmed.ncbi.nlm.nih.gov/36441983/
This article is for general education and is not medical advice. NUUD is a botanical supplement for desire, is not a treatment for depression or any other condition, and is not a substitute for care from a licensed clinician. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Do not start, stop, reduce, or change any prescribed medication without speaking to the person who prescribed it. If you are having thoughts of hurting yourself, call or text 988 in the US.
